Abstract:
:Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate stage HCC, including those with large or multinodular HCC, well-preserved liver function, and no cancer-related symptoms or evidence of vascular invasion or extrahepatic spread. Two TACE techniques have been used since 2004, conventional TACE (cTACE) and TACE with drug-eluting beads (DEB-TACE). cTACE was evidenced first to treat intermediate stage HCC patients. It combines the transcatheter delivery of chemotherapy using Lipiodol-based emulsion plus an embolizing agent to achieve strong cytotoxic and ischemic effects. Drug-eluting beads (DEBs) were developed in order to slowly release chemotherapeutic agents, and to increase ischemia intensity and duration. Recent advances allow TACE treatment of both early stage patients (i.e. those with a solitary nodule or up to 3 nodules under 3 cm) and some advanced stage patients. Here we review recent clinical evidence related to TACE treatment of patients with early, intermediate, and advanced stage HCC. Based on the 2014 TACE algorithm of Raoul et al., this international expert panel proposes an updated TACE algorithm and provides insights into TACE use for patients at any HCC stage.
journal_name
Cancer Treat Revjournal_title
Cancer treatment reviewsauthors
Raoul JL,Forner A,Bolondi L,Cheung TT,Kloeckner R,de Baere Tdoi
10.1016/j.ctrv.2018.11.002subject
Has Abstractpub_date
2019-01-01 00:00:00pages
28-36eissn
0305-7372issn
1532-1967pii
S0305-7372(18)30194-4journal_volume
72pub_type
杂志文章,评审abstract::The use of agents able to modulate the immune system to induce or potentiate its anti-tumour activity is not a new strategy in oncology. However, the development of new agents such as immune checkpoint inhibitors has achieved unprecedented efficacy results in a wide variety of tumours, dramatically changing the landsc...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2017.01.008
更新日期:2017-03-01 00:00:00
abstract::Tissue hypoxia occurs where there is an imbalance between oxygen supply and consumption. Hypoxia occurs in solid tumours as a result of an inadequate supply of oxygen, due to exponential cellular proliferation and an inefficient vascular supply. It is an adverse prognostic indicator in cancer as it is associated with ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(03)00003-3
更新日期:2003-08-01 00:00:00
abstract::Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2015.06.007
更新日期:2015-09-01 00:00:00
abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(93)90004-b
更新日期:1993-04-01 00:00:00
abstract::The clinical trials of bisantrene are still at an early stage. However, the many Phase II trials currently ongoing in the Southwest Oncology Group are too premature to draw any firm conclusions. However, there was general agreement during the discussion period that bisantrene does have definite clinical activity in ce...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(84)90024-0
更新日期:1984-12-01 00:00:00
abstract::Glioblastoma is the most malignant and frequent primary brain tumour in adults. Current treatment remains insufficient as these tumours display a diffuse infiltrative growth pattern and tend to recur despite extensive debulking surgery followed by radio- and chemotherapy. The alkylating agents carmustine (1,3-bis-(2-c...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.03.125
更新日期:2008-10-01 00:00:00
abstract::Historically, the median overall survival for patients with stage IV melanoma was less than 1 year and the 5-year survival rate was ∼10%. Recent advances in therapy have raised 5-year survival expectations to ∼20%. Notably, a subset of melanoma patients who receive immunotherapy with high-dose interleukin-2, and now i...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2014.06.012
更新日期:2014-10-01 00:00:00
abstract::Despite improvements in the management of patients with early breast cancer, the prognosis for women with locally advanced breast cancer (LABC) remains poor. The potential goals of neoadjuvant treatment for this disease include down-sizing tumours to allow breast conservation as well as the possibility of improving su...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2004.09.008
更新日期:2005-02-01 00:00:00
abstract::Six major randomized clinical trials evaluating the role of taxanes in the adjuvant setting of breast cancer have demonstrated significant improvements in terms of efficacy in favour of the taxane treatment arm. In all cases, different anthracycline-based regimens were used as the control arm. Nevertheless, many clini...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2007.04.006
更新日期:2007-08-01 00:00:00
abstract::In the early stages of this phase I study the tolerance of carboplatin intraperitoneally was good. Pharmacokinetic profiles suggest a possible therapeutic advantage for giving the drug intraperitoneally for the treatment of tumour nodules situated in the peritoneum. The extent of penetration of carboplatin through tum...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(85)90016-7
更新日期:1985-09-01 00:00:00
abstract::Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(90)90055-k
更新日期:1990-09-01 00:00:00
abstract::Patients with malignant disease may need hormonal therapy as primary or adjuvant treatment or for palliation. Oestrogens usually decrease serum levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), increase high density lipoprotein cholesterol (HDL-C) concentration, but induce an elevation ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.09.007
更新日期:2009-04-01 00:00:00
abstract::The prognosis for patients with relapsed/progressive non-small cell lung cancer (NSCLC) remains poor. For first-line therapy, a number of platinum-based regimens are standard; second-line therapies include single-agent docetaxel, pemetrexed, and erlotinib. Treatment options for patients whose tumors have failed to res...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2012.05.003
更新日期:2013-05-01 00:00:00
abstract::Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposur...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2019.101896
更新日期:2019-11-01 00:00:00
abstract::The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next-generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic effica...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2015.12.003
更新日期:2016-02-01 00:00:00
abstract::From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1053/ctrv.1999.0152
更新日期:2000-04-01 00:00:00
abstract::Aflibercept, also known as vascular endothelial growth factor (VEGF)-Trap, is a recombinant, decoy receptor fusion protein, rationally designed to block angiogenesis by targeting not only all forms of VEGF-A, but also VEGF-B and placental growth factor. It inhibits VEGF-induced angiogenesis in preclinical models. In t...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2011.12.008
更新日期:2012-08-01 00:00:00
abstract::In the last ten years, the development of several novel targeted drugs and the refinement of state of the art technologies such as the genomics and proteomics and their introduction to clinical practice have revolutionized the management of patients affected by cancer. However, everyday practice points out several cli...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2007.10.001
更新日期:2008-04-01 00:00:00
abstract::We have previously shown that the stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK monomer) leads to a good tolerance of otherwise lethal multiple ara-C doses and an increased survival of ara-C + peptide treated mice. This effect was due to the prevention of drug-induced CFU-S proliferation, thus keeping stem...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/0305-7372(90)90068-q
更新日期:1990-09-01 00:00:00
abstract::Vinorelbine is a semi-synthetic vinca alkaloid that has been shown active in many tumour types and is currently registered for the treatment of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC). This agent has a generally favourable safety profile, and may be suitable for use in special populations s...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2005.12.008
更新日期:2006-04-01 00:00:00
abstract::Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10 years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, ther...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2015.06.002
更新日期:2015-09-01 00:00:00
abstract::Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers and remains a challenge in oncology. In 1997, gemcitabine became the standard of care in metastatic setting. In the last decades, despite a number of clinical trials assessing novel cytotoxic agents and cell signaling inhibitors, overall sur...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.10.002
更新日期:2009-04-01 00:00:00
abstract::Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. Howe...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2013.06.008
更新日期:2014-02-01 00:00:00
abstract::Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water. The current pharmaceutical formulation consists of a ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(97)90022-0
更新日期:1997-03-01 00:00:00
abstract::Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/s0305-7372(06)80001-0
更新日期:2006-01-01 00:00:00
abstract::Solid tumours contain regions of hypoxia, which may be a prognostic indicator and determinant of malignant progression, metastatic development and chemoradio-resistance. The degree of intra-tumoural hypoxia has been shown to be positively correlated with the expression of the transcription factor hypoxia-inducible fac...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2006.05.003
更新日期:2006-10-01 00:00:00
abstract::Patients diagnosed with advanced gastrointestinal stromal tumor (GIST) are currently treated with oral tyrosine kinase inhibitors (TKIs). Imatinib mesylate is the standard first-line treatment, and sunitinib malate is administered second-line for patients who are intolerant or progress on imatinib. Imatinib has recent...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2010.04.008
更新日期:2011-02-01 00:00:00
abstract::Single-fraction stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (SRT) are radiation planning and delivery techniques used for the treatment of intracranial and spine/spinal cord tumors and targets. For cranial SRS and SRT, critical normal tissues/structures include the brainstem, cranial...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2011.04.004
更新日期:2011-11-01 00:00:00
abstract::The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib have been incorporated into treatment paradigms for patients with advanced non-small cell lung cancer. These agents are particularly effective in a subset of patients whose tumors harbor activating epidermal growth...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2011.01.003
更新日期:2011-10-01 00:00:00
abstract::Metastatic cervical carcinoma from unknown primary is a metastatic disease in the lymph nodes of the neck without any evidence of a primary tumour after appropriate investigation. The condition is rare and definite evidence is lacking for both diagnosis and treatment. In this review of the literature, we tried to draw...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2016.11.014
更新日期:2017-02-01 00:00:00